Extension of strategic alliance with Summit
Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
Spinout Perspectum secures FDA clearance, closes $5m round
Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.
Spinout OrganOx gets European regulatory approval
Oxford University Innovation spinout OrganOx has received CE mark certification for its OrganOx metra device, which improves the success of liver transplantation.
NightstaRx closes $35 million Series B funding to advance Inherited Retinal Disease pipeline
Oxford University Innovation spinout NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, has announced a $35 million Series B financing round.
An innovation community: Oxford
Outside London, it is arguable that no other region has had more of an effect on the evolution of the UK than Oxford. From custodians of the English language to leaders of the country, Oxford has continued to have a major impact on the shape and destiny of the British people.
Spin-out successes recognised in OBN 2015 Awards
Outstanding achievement in the UK Life Sciences sector is celebrated in the annual OBN Awards ceremony. Five spin-outs from Oxford featured in this year’s awards, presented on 1st October.
© Oxford University Innovation